Zydus Lifesciences Limited has announced a board-approved share buyback program of up to ₹1,100 crore. The company intends to repurchase a maximum of 95,65,217 equity shares, representing approximately 0.95% of its total paid-up share capital. The buyback will be conducted at a price of ₹1,150 per share via the tender offer route, with the record date set for May 29, 2026.
Strategic Share Repurchase Program
The Board of Directors of Zydus Lifesciences Limited, in their meeting held on May 19, 2026, has formally approved a proposal to buy back equity shares of the company. This initiative involves an aggregate cash outlay of up to ₹1,100 crore, excluding transaction-related expenses. The company aims to repurchase up to 95,65,217 fully paid-up equity shares, which accounts for 0.95% of its total equity base as of March 31, 2026.
Buyback Details and Record Date
The shares will be repurchased at a price of ₹1,150 per share. The buyback will be executed through the tender offer route, ensuring a proportionate participation from shareholders. The company has designated Friday, May 29, 2026, as the record date for determining the eligibility of equity shareholders to participate in this offer.
Operational Execution
To facilitate the process, the company has constituted a Buyback Committee, which is authorized to manage all necessary arrangements, including the appointment of intermediaries, opening of bank accounts, and overseeing the finalization of the offer timeline. The company has engaged ICICI Securities Limited as the manager to the buyback, and MUFG Intime India Private Limited will serve as the registrar for the process. Post-completion, the company is committed to extinguishing the repurchased shares to reduce its outstanding share capital.
Source: BSE
